Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Verstovsek, S.; Mesa, R.; Gotlib, J.; Gupta, Vikas; Dipersio, J.; Catalano, J.; Deininger, M.; B. Miller, Carole; Silver, R.; Talpaz, M.; Winton, E.; Harvey, J.; Arcasoy, M.; Hexner, E.; Lyons, R.; Paquette, R.; Raza, A.; M. Jones, Mark; Kornacki, D.; Sun, K.; Kantarjian, H.

doi:10.1186/s13045-017-0417-z

Public

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Shared by NobleBlocks on Feb 22, 2017 • 12:00 AM UTC

Authors:

S. Verstovsek

R. Mesa

J. Gotlib

Abstract

BackgroundThe randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis. The primary and planned 3-year analyses of COMFORT-I data demonstrated that ruxolitinib—the first myelofibrosis-a...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!